1.17
price up icon1.74%   0.02
after-market Dopo l'orario di chiusura: 1.18 0.01 +0.85%
loading
Precedente Chiudi:
$1.15
Aprire:
$1.17
Volume 24 ore:
2.32M
Relative Volume:
0.46
Capitalizzazione di mercato:
$241.80M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-0.5519
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+14.71%
1M Prestazione:
+11.43%
6M Prestazione:
-46.58%
1 anno Prestazione:
-50.42%
Intervallo 1D:
Value
$1.15
$1.215
Intervallo di 1 settimana:
Value
$0.949
$1.215
Portata 52W:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Nome
Esperion Therapeutics Inc
Name
Telefono
734-887-3903
Name
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Dipendente
304
Name
Cinguettio
@esperioninc
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
ESPR's Discussions on Twitter

Confronta ESPR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
1.17 241.80M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
22.99 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.18 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.25 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.34 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.01 20.17B 16.54B -1.64B 749.00M -1.45

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-18 Iniziato Goldman Neutral
2024-12-17 Iniziato Cantor Fitzgerald Overweight
2024-06-20 Downgrade BofA Securities Neutral → Underperform
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-20 Ripresa JP Morgan Neutral
2023-08-01 Aggiornamento Northland Capital Under Perform → Market Perform
2023-06-15 Aggiornamento BofA Securities Underperform → Buy
2023-03-16 Downgrade BofA Securities Neutral → Underperform
2023-03-16 Downgrade Northland Capital Market Perform → Under Perform
2023-03-07 Aggiornamento Credit Suisse Underperform → Neutral
2023-02-27 Ripresa BofA Securities Neutral
2023-02-24 Aggiornamento Jefferies Hold → Buy
2023-02-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-08-03 Downgrade Credit Suisse Neutral → Underperform
2022-05-05 Aggiornamento JP Morgan Underweight → Neutral
2022-03-10 Iniziato H.C. Wainwright Buy
2021-10-19 Downgrade Credit Suisse Outperform → Neutral
2021-10-14 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-05-05 Downgrade Stifel Buy → Hold
2021-04-26 Ripresa Credit Suisse Outperform
2021-03-11 Iniziato Morgan Stanley Equal-Weight
2021-02-12 Downgrade Jefferies Buy → Hold
2021-02-09 Downgrade Goldman Neutral → Sell
2021-01-15 Downgrade BofA Securities Buy → Neutral
2020-11-10 Aggiornamento Credit Suisse Neutral → Outperform
2020-09-29 Ripresa JP Morgan Underweight
2020-08-11 Downgrade Credit Suisse Outperform → Neutral
2020-04-01 Ripresa BofA/Merrill Buy
2020-03-17 Aggiornamento Citigroup Neutral → Buy
2020-02-24 Downgrade Northland Capital Outperform → Market Perform
2020-02-14 Downgrade Citigroup Buy → Neutral
2019-09-16 Aggiornamento Goldman Sell → Neutral
2019-05-29 Downgrade Goldman Neutral → Sell
2019-05-06 Aggiornamento BofA/Merrill Underperform → Neutral
2019-04-26 Aggiornamento Goldman Sell → Neutral
2019-03-13 Aggiornamento JP Morgan Underweight → Neutral
2019-01-07 Reiterato Needham Strong Buy
2018-12-13 Iniziato Goldman Sell
2018-10-29 Aggiornamento Northland Capital Market Perform → Outperform
2018-10-16 Iniziato BTIG Research Buy
2018-08-17 Aggiornamento Citigroup Neutral → Buy
2018-07-11 Downgrade Northland Capital Outperform → Market Perform
2018-05-03 Downgrade JP Morgan Neutral → Underweight
2018-05-02 Downgrade BofA/Merrill Buy → Underperform
Mostra tutto

Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie

pulisher
Jun 17, 2025

ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus

Jun 17, 2025
pulisher
Jun 14, 2025

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha

Jun 14, 2025
pulisher
Jun 13, 2025

Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 07, 2025

Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 04, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia

Jun 04, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Boosts Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Esperion settles patent case with Hetero USA over cholesterol drug By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Esperion settles patent case with Hetero USA over cholesterol drug - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion reaches settlement agreement with Hetero USA, affiliates - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion (ESPR) Reaches Settlement to Protect NEXLETOL Patents | ESPR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DE - Defense World

May 31, 2025
pulisher
May 31, 2025

Deutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 31, 2025
pulisher
May 31, 2025

Zacks Research Has Pessimistic Outlook of ESPR Q2 Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLC - Defense World

May 30, 2025
pulisher
May 30, 2025

Zacks Research Has Positive Outlook of ESPR FY2027 Earnings - Defense World

May 30, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Has $337,000 Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 27, 2025
pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Grows Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 26, 2025
pulisher
May 24, 2025

Northern Trust Corp Buys 65,662 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 24, 2025
pulisher
May 21, 2025

Esperion Therapeutics discovers new ATP citrate lyase inhibitors - BioWorld MedTech

May 21, 2025
pulisher
May 20, 2025

Esperion to Participate in Upcoming June Investor Conferences - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Esperion at H.C. Wainwright Conference: Strategic Growth and Future Plans - Investing.com

May 20, 2025
pulisher
May 20, 2025

Esperion to Present Latest Cardiovascular Drug Developments at Goldman Sachs, Jefferies Healthcare Events - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Average Target Price from Brokerages - Defense World

May 20, 2025
pulisher
May 15, 2025

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival - insights.citeline.com

May 15, 2025
pulisher
May 14, 2025

Raymond James Financial Inc. Invests $98,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 14, 2025
pulisher
May 12, 2025

Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Esperion reaches settlement agreement with Micro Labs - TipRanks

May 12, 2025
pulisher
May 12, 2025

Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Esperion (ESPR) Reaches Settlement with Micro Labs Over Patent Dispute | ESPR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Esperion Settles Patent Litigation with Micro Labs Regarding NEXLETOL Generic Marketing Rights - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Esperion Reaches Settlement Agreement with ANDA Filer Not - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - Stock Titan

May 12, 2025
pulisher
May 11, 2025

Cantor Fitzgerald Has Negative View of ESPR FY2025 Earnings - Defense World

May 11, 2025
pulisher
May 10, 2025

Needham & Company LLC Cuts Esperion Therapeutics (NASDAQ:ESPR) Price Target to $4.00 - Defense World

May 10, 2025
pulisher
May 09, 2025

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail

May 09, 2025
pulisher
May 09, 2025

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - GlobeNewswire

May 09, 2025
pulisher
May 08, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Esperion at The Citizens JMP Life Sciences Conference: Strategic Growth Insights - Investing.com India

May 08, 2025

Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Esperion Therapeutics Inc Azioni (ESPR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Koenig Sheldon L.
President and CEO
Jun 17 '25
Sale
1.11
30,474
33,796
1,541,488
Halladay Benjamin
Chief Financial Officer
Jun 17 '25
Sale
1.15
7,229
8,328
474,473
$14.64
price down icon 0.54%
$9.32
price down icon 0.21%
$129.11
price down icon 0.22%
$294.49
price down icon 0.25%
drug_manufacturers_specialty_generic RDY
$15.08
price up icon 1.34%
$17.01
price down icon 0.23%
Capitalizzazione:     |  Volume (24 ore):